Characterization of drug-binding levels to serum albumin using a wavelength modulation surface plasmon resonance sensor

Sensors and Actuators, B: Chemical

Volumn 117, Issue 1, 2006, Pages 188-195

  Liu, Xia ^a,b   Song, Daqian ^a   Zhang, Qinglin ^a   Tian, Yuan ^a   Liu, Zhongying ^a   Zhang, Hanqi ^a,b  

^a JILIN UNIVERSITY   (China)

^b HUNAN UNIVERSITY   (China)

Author keywords

Affinity; BSA; Drug; HSA; SPR; Wavelength modulation

Indexed keywords

MODULATION; MOLECULAR WEIGHT; RATE CONSTANTS; SENSORS; SURFACE PLASMON RESONANCE; WAVES;

AFFINITY; BOVINE SERUM ALBUMIN (BSA); DRUG; HUMAN SERUM ALBUMIN (HSA); WAVELENGTH MODULATION;

DRUG INTERACTIONS;

EID: 33745944468     PISSN: 09254005     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.snb.2005.11.023     Document Type: Article

References (32)

1. Peter T.J. All About Albumin. Biochemistry, Genetics and Medical Applications (1996), Academic Press, California
2. Goodman G.A., and Gilman. The Pharmacological Basis of Therapeutics. 9th ed. (1996), McGraw-Hill, New York
3. Colmenarejo G. In silico prediction of drug-binding strengths to human serum albumin. Med. Res. Rev. 23 (2003) 275-301
4. Bhattacharya A.A., Grune T., and Curry S. Crystallographic analysis reveals common modes of binding of medium and long-chain fatty acids to human serum albumin. J. Mol. Biol. 303 (2000) 721-732
5. Anna S. Interaction of drugs with bovine and human serum albumin. J. Mol. Struct. 614 (2002) 227-232
6. Watanbe H., Tanase S., Nakajou K., Maruyama T., Kragh-Hansen U., and Otagiri M. Role of Arg-410 and Tyr-411 in human serum albumin for ligand binding and esterase-like activity. Biochem. J. 349 (2000) 813-819
7. Petitpas I., Bhattacharya A.A., Twine S., East M., and Curry S. Crystal structure analysis of warfarin binding to human serum albumin. J. Biol. Chem. 276 (2001) 22804-22809
8. Petitpas I., Grune T., Bhattacharya A.A., and Curry S. Crystal structures of human serum albumin complexed with monounsaturated and polyunsaturated fatty acids. J. Mol. Biol. 314 (2001) 955-960
9. Qin M., Nilsson M., and Oie S. Decreased elimination of drug in the presence of alpha-1-acid glycoprotein is related to a reduced hepatocyte uptake. J. Pharmcol. Exp. Ther. 269 (1994) 117-181
10. Benet L.Z., Kroetz D.L., and Sheiner L.B. Pharmacokinetics. In: Goodman G.A., and Gilman (Eds). The Pharmacological Basis of Therapeutics. 9th ed. (1996), McGraw-Hill, New York 3-27
11. Jia Z.G., Ramstad T., and Zhong M. Determination of protein-drug binding constants by pressure-assisted capillary electrophoresis (PACE) frontal analysis (FA). J. Pharm. Biomed. Anal. 30 (2002) 405-413
12. Qstergaard J., Schou C., Larsen1 C., and Heegaard N.H.H. Evalution of capillary electrophoresis-frontal analysis for the study of low molecular weight drug-human serum albumin interactions. Electrophoresis 23 (2002) 2842-2853
13. Ding Y.S., Lin B.C., and Huie C.W. Binding studies of porphyrins to human serum albumin using affinity capillary electrophoresis. Electrophoresis 22 (2001) 2210-2216
14. Xu B.Q., Ishii M., Ding L.R., Fischer N.E., and Inaba T. Interaction of serum proteins with CYP isoforms in human liver microsomes: inhibitory effects of human and bovine albumin, alpha-globulins, alpha-1-acid glycoproteins and gamma-globulins on CYP2C19 and CYP2D6. Life Sci. 72 (2003) 1953-1962
15. Il'ichev Y.V., Perry J.L., Ruker F., Dockal M., and Simon J.D. Interaction of ochratoxin A with human serum albumin. Binding sites localized by competitive interactions with the native protein and its recombinant fragments. Chem. Biol. Interact. 141 (2002) 275-293
16. Messori L., Piccioli F., Gabrielli S., Orioli P., Angeloni L., and Bugno C.D. Bioorg. The disaccharide anthracycline MEN 10755 binds humanserum albumin to a non-classical drug binding site. Med. Chem. 10 (2002) 3425-3430
17. Fitos I., Visy J., and Simonyi M. Species-dependency in chiral-drug recognition of serum albumin studied by chromatographic methods. J. Biochem. Biophys. Methods 54 (2002) 71-84
18. de Mol N.J., Plomp E., Fischer M.J.E., and Ruijtenbeek R. Kinetic analysis of the mass transport limited interaction between the tyrosine kinase lck SH2 domain and a phosphorylated peptide studied by a new cuvette-based surface plasmon resonance instrument. Anal. Biochem. 279 (2000) 61-70
19. Stenlund P., Babcock G.J., Sodroski J., and Myszka D.G. Capture and reconstitution of G protein-coupled receptors on a biosensor surface. Anal. Biochem. 316 (2003) 243-250
20. Tripet B., Crescenzo G.D., Grothe S., O'Connor-McCourt M., and Hodges R.S. Kinetic analysis of the interactions between Troponin C (TnC) and Troponin I (TnI) binding peptides: evidence for separate binding sites for the 'structural' N-terminus and the 'regulatory' C-terminus of TnI on TnC. J. Mol. Recognit. 16 (2003) 37-53
21. Liu X., Wei J.Y., Song D.Q., Zhang Z.W., Zhang H.Q., and Luo G.M. Determination of affinities and antigenic epitopes of bovine cardiac troponin I (cTnI) with monoclonal antibodies by surface plasmon resonance biosensor. Anal. Biochem. 314 (2003) 301-309
22. Gambari R., Feriotto G., Rutigliano C., Bianchi N., and Mischiati C. Biospecific interaction analysis (BIA) of low-molecular weight DNA-binding drugs. J. Pharmcol. Exp. Ther. 294 (2000) 370-377
23. Baird C.L., Courtenay E.S., and Myszka D.G. Surface plasmon resonance characterization of drug/liposome interactions. Anal. Biochem. 310 (2002) 93-99
24. Danelian E., Karlén A., Karlsson R., Winiwarter S., Hansson A., Löfås S., Lennernäs H., and Hämä läinen M.D. SPR biosensor studies of the direct interaction between 27 drugs and a liposome surface: correlation with fraction absorbed in humans. J. Med. Chem. 43 (2000) 2083-2086
25. Rich R.L., Day Y.S.N., Morton T.A., Myszka1 D.G., Danelian E., Karlén A., Karlsson R., Winiwarter S., Hansson A., Löfås S., Lennernäs H., and Hämä läinen M.D. SPR biosensor studies of the direct interaction between 27 drugs and a liposome surface. Anal. Biochem. 296 (2001) 197-207
26. Frostell-Karlsson A., Remaeus A., Roos H., Andersson K., Borg P., Hämä läinen M., and Karlsson R. Biosensor analysis of the interaction between immobilized human serum albumin and drug compounds for prediction of human serum albumin binding levels. J. Med. Chem. 43 (2000) 1986-1992
27. Nay Y.S.N., and Myszka D.G. Characterizing a drug's primary binding site on albumin. J. Pharm. Sci. 92 (2003) 333-343
28. Ahmad A., Ramakrishnan A., Mclean M.A., and Breau A.P. Use of surface plasmon resonance biosensor technology as a possible alternative to detect differences in binding of enantiomeric drug compounds to immobilized albumin. Biosens. Bioelectron. 18 (2003) 399-404
29. Ober R.J., Caves J., and Ward E.S. Analysis of exponential data using a non-iterative technique: application to surface plasmon experiments. Anal. Biochem. 312 (2003) 57-65
30. Torsten F., Michael B., and Karl-Wilhelm K. Application of different surface plasmon resonance biosensor chips to monitor the interaction of the CaM-binding site of nitric oxide synthase I and calmodulin. Biochem. Biophys. Res. Commun. 285 (2001) 463-469
31. Nerli B., Romanini D., and Pico G. Structural specificity requirements in the binding of beta lactam antibiotics to serum albumin. Chem. Biol. Interact. 104 (1997) 179-202
32. Zlotos G., Oehlmann M., Nickel P., and Hzgrabe U. Determination of protein binding of gyrase inhibitors by means of continuous ultrafiltration. J. Pharm. Biomed. Anal. 18 (1998) 847-858